Philips (NYSE: PHG) announced today it has reinforced its strategic alliance with Sim&Cure. Known for their cutting-edge digital approaches in neurovascular therapies, Sim&Cure initially partnered with Philips, which is based in Amsterdam, five years ago. Now, they are embarking on a new stage to strengthen Philips’ standing within the interventional neuro field.
A press release indicates that both companies aim to incorporate Sim&Size software into Philips’ forthcoming iteration of its Azurion image-guided therapy platform. This advanced integration promises to offer healthcare professionals a more cohesive, user-friendly, and efficient workflow for managing intricate brain aneurysms.
Moreover, the partnership seeks to foster new synergies through collaborative initiatives, driving future innovation in cathlabs.
“We are thrilled to deepen our partnership with Philips to amplify our joint influence in neurovascular therapy. Our collective solutions empower clinicians to meticulously plan and conduct minimally invasive procedures, leveraging the combined innovations from both companies for superior patient care,” said Mathieu Sanchez, CEO of Sim&Cure.
Philips emphasizes that this venture mirrors its ongoing resolve to deliver integrated solutions, supporting every step in the stroke care pathway.
“The intensified partnership with Sim&Cure enables us to merge simulation and image-guided therapy into one cohesive platform, boosting physician confidence and enhancing patient results,” stated Nicole Hermkens, VP of marketing for IGT Systems at Philips. “Incorporating Sim&Size™ into our Azurion platform streamlines complexity and reduces variability in neurovascular procedures, ultimately addressing the increasing challenge of brain aneurysms.”
Menu
Menu